Operating Grants: Bringing Rare Disease Gene Therapies to Clinical Trial Readiness
National Research Council Applicant Partner Fiche
The National Research Council of Canada (NRC) is the Government of Canada’s largest research and development (R&D) organization. The NRC works with academic and industry partners to advance knowledge by applying leading-edge technologies to find creative, relevant, and sustainable solutions to Canada’s current and future economic, social and environmental challenges.
The NRC – Human Health Therapeutics (NRC-HHT) Research Centre aims to transform human health outcomes for the benefit of society in collaboration with private and public sector organization. Its mission is to accelerate the discovery and development of innovative medicines in Canada, including:
- Advanced biologics, e.g., vaccines, antibody-based therapies, etc.
- Biomanufacturing
- Cell and gene therapy
This funding opportunity leverages the NRC’s expertise in viral vector design, optimization, and biomanufacturing to enable partners to advance research that leads to first-in-human clinical trials for gene therapy. As part of the Government of Canada’s National Strategy for Drugs for Rare Diseases to bring gene therapies to clinical trial readiness, the NRC-HHT will partner with up to two (2) successfully funded projects.
NRC-HHT support will not include additional funds beyond those provided by the funding opportunity. NRC-HHT support may include:
- Providing scientific expertise and advice as well as guidance for completing Full Applications;
- Facilitating connections with industry experts and other research institutions and platforms; and/or
- Planning future collaborations and support for experimental/laboratory work.
Specific areas of collaboration and support will be determined between the Applicant and NRC-HHT. Applicants successful at the Letter of Intent Stage will be provided with NRC-HHT contact information to work together to complete the Full Application.
- Date modified: